Table 5.
Characteristics of some paclitaxel nanoparticles
| Formulation | Composition | Particle size (nm) |
Solubility (mg/mL) |
Reference |
|---|---|---|---|---|
| Paclitaxel PVP-b-PDLLA nanoparticles | Poly(N-vinylpyrrolidone)-block-poly(d,l-lactide) | 56 or 16 | ≥2.5 | [16] |
| Paclitaxel PDLLA-MePEG micelles | Amphiphilic diblock copolymer of poly (D,L- lactide)-block-methoxy polyethylene glycol | <50 | 5 | [17] |
| Paclitaxel PEG-b-P(VBODENA) micelles | Diblock copolymer of poly(ethylene glycol) (PEG)- b-poly(2-(4-vinylbenzyloxy)-N,N- diethylnicotinamide) | 105 | ≥38.9 | [18] |
| Paclitaxel-PEG2000-PE/TPGS micelles | Poly(ethylene glycol)2000–phosphatidyl ethanolamine conjugate d-α-tocopheryl polyethylene glycol 1000 succinate | 14–15 | 5 | [19] |
| Paclitaxel-PEG-HCCs formulation | PEGylated hydrophilic carbon clusters | <40 | 1.6 | [20] |
| Paclitaxel-Pluronic P123 micelles | Pluronic P123 | 25 | ≥0.3 | [21] |
| Paclitaxel-Pluronic F127 Nanocrystal | Pluronic F127 | 122 | ≥2 | [22] |
| Paclitaxel-DHC micelles | N-deoxycholic acid-N, O-hydroxyethyl chitosan | 200–240 | ≥2 | [23] |
| Cremophor EL | Cremophor EL, ethanol | 0 | ≥6.3 | [24] |
| PTX-RUB | RUB | 7 | 6.3 | This study |